source
- UniQure prepares for FDA advisory committee on Huntington’s gene therapy amid rare-disease regulatory jittersUniQure said it is ready to present its Huntington's disease gene therapy, AMT-130, to an FDA advisory committee, as discussed in its Q2 earnings call. The company expects the FDA may schedule the…
- Trump administration proposes 340B rebate pilot for 2027, hospitals push backThe Health Resources and Services Administration announced a new pilot that would shift some 340B drug discounts to rebate payments starting in 2027. The proposal follows a previous attempt earlie…